The Long Beach-based insurer saw its stock sink to $121.16 in premarket trading, extending a year-long decline that has erased nearly 38% of its market value. The volatility follows a fourth-quarter report marred by persistent medical-cost pressure across Medicare and marketplace segments, alongside retroactive premium adjustments tied to the company’s Medicaid business in California.

A Wide Miss on Guidance

The disparity between Molina’s internal projections and analyst estimates is stark. For the full year, the company expects earnings of at least $3.20 per share, or $5.00 on an adjusted basis. This stands in sharp contrast to the $13.66 adjusted earnings per share anticipated by analysts polled by FactSet. Chief Executive Joe Zubretsky attributed the shortfall largely to the underperformance of the company’s Medicare Advantage Part D (MAPD) product, which covers prescription drugs.

In response to these headwinds, Zubretsky announced a significant pivot in the company’s Medicare strategy. Molina plans to fully exit the traditional MAPD market by 2027, choosing instead to focus resources exclusively on dual-eligible members—those who qualify for both Medicare and Medicaid. The CEO told analysts that the current prescription drug product no longer aligns with the company’s long-term strategic shift toward more specialized member segments.

Despite the immediate financial blow, management expressed confidence that the operating platform remains sustainable. The insurer is currently navigating a period of volatility as the rate environment returns to equilibrium, following a quarter that Zubretsky described as disappointing but manageable within the company's broader durable framework.